Zhejiang CONBA Pharmaceutical Co Ltd (600572) — Tangible Net Worth Ratio
Zhejiang CONBA Pharmaceutical Co Ltd (600572) has a Tangible Net Worth Ratio of 95.0% as of March 2026. This metric is calculated by deducting intangible assets (CN¥365.30 Million) from net assets (CN¥7.37 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset momentum of Zhejiang CONBA Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Zhejiang CONBA Pharmaceutical Co Ltd Tangible Net Worth Ratio (2001–2025)
This chart shows how Zhejiang CONBA Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 25 annual periods from 2001 to 2025. As of March 2026, the ratio stands at 95.0%, reflecting net assets of CN¥7.37 Billion with intangible assets of CN¥365.30 Million CNY. For live market cap and overall valuation, see Zhejiang CONBA Pharmaceutical Co Ltd (600572) total market value.
Annual Tangible Net Worth Ratio for Zhejiang CONBA Pharmaceutical Co Ltd (2001–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2025, covering 25 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore capital reinvestment ratio of Zhejiang CONBA Pharmaceutical Co Ltd to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.8% | CN¥7.15 Billion | CN¥371.95 Million | CN¥9.98 Billion | ▲ +0.4 pp |
| 2024 | 94.4% | CN¥6.91 Billion | CN¥389.62 Million | CN¥9.90 Billion | ▼ -0.6 pp |
| 2023 | 95.0% | CN¥7.35 Billion | CN¥369.84 Million | CN¥11.24 Billion | ▲ +0.3 pp |
| 2022 | 94.7% | CN¥7.32 Billion | CN¥390.79 Million | CN¥10.93 Billion | ▼ -0.4 pp |
| 2021 | 95.1% | CN¥7.39 Billion | CN¥362.04 Million | CN¥10.79 Billion | ▲ +2.2 pp |
| 2020 | 92.9% | CN¥5.35 Billion | CN¥377.82 Million | CN¥9.28 Billion | ▲ +1.0 pp |
| 2019 | 91.9% | CN¥4.94 Billion | CN¥398.51 Million | CN¥9.86 Billion | ▲ +0.0 pp |
| 2018 | 91.9% | CN¥5.79 Billion | CN¥467.74 Million | CN¥10.71 Billion | ▼ -0.1 pp |
| 2017 | 92.0% | CN¥5.84 Billion | CN¥464.98 Million | CN¥9.42 Billion | ▲ +2.8 pp |
| 2016 | 89.3% | CN¥4.49 Billion | CN¥481.91 Million | CN¥8.50 Billion | ▲ +2.2 pp |
| 2015 | 87.1% | CN¥4.57 Billion | CN¥589.58 Million | CN¥9.57 Billion | ▲ +1.9 pp |
| 2014 | 85.2% | CN¥3.37 Billion | CN¥499.65 Million | CN¥6.30 Billion | ▼ -1.9 pp |
| 2013 | 87.0% | CN¥2.59 Billion | CN¥336.11 Million | CN¥4.45 Billion | ▼ -1.7 pp |
| 2012 | 88.8% | CN¥2.44 Billion | CN¥274.08 Million | CN¥4.54 Billion | ▲ +0.0 pp |
| 2011 | 88.8% | CN¥1.61 Billion | CN¥181.33 Million | CN¥2.96 Billion | ▼ -1.5 pp |
| 2010 | 90.3% | CN¥1.72 Billion | CN¥166.67 Million | CN¥2.46 Billion | ▲ +5.3 pp |
| 2009 | 85.0% | CN¥1.15 Billion | CN¥172.63 Million | CN¥1.93 Billion | ▼ -5.9 pp |
| 2008 | 90.9% | CN¥919.66 Million | CN¥84.06 Million | CN¥1.57 Billion | ▲ +1.8 pp |
| 2007 | 89.0% | CN¥854.74 Million | CN¥93.72 Million | CN¥1.55 Billion | ▲ +1.3 pp |
| 2006 | 87.7% | CN¥627.66 Million | CN¥77.23 Million | CN¥1.26 Billion | ▲ +1.0 pp |
| 2005 | 86.7% | CN¥595.08 Million | CN¥78.93 Million | CN¥1.16 Billion | ▼ -1.9 pp |
| 2004 | 88.6% | CN¥565.05 Million | CN¥64.26 Million | CN¥981.41 Million | ▼ -6.2 pp |
| 2003 | 94.9% | CN¥239.44 Million | CN¥12.32 Million | CN¥581.65 Million | ▲ +2.2 pp |
| 2002 | 92.7% | CN¥200.75 Million | CN¥14.66 Million | CN¥462.63 Million | ▲ +1.6 pp |
| 2001 | 91.1% | CN¥181.89 Million | CN¥16.24 Million | CN¥447.63 Million | — |